Pharmacokinetic optimisation of cancer chemotherapy. Effect on outcomes.

abstract：:Pregnancy is a specific dynamic state, and the potential usefulness of caring for a disorder in the fetus or the mother is now well established. Previously, pregnant women have been excluded from clinical trials, therefore only a few studies concerning evaluation of the pregestational metabolism or transplacental tran...

journal_title：Clinical pharmacokinetics

authors： Bourget P,Roulot C,Fernandez H

更新日期：1995-02-01 00:00:00

abstract：:Acute coronary syndromes (ACS) remain life-threatening disorders associated with high morbidity and mortality, despite advances in treatment over the last decade. Adenosine diphosphate-induced platelet activation via P2Y(12) receptors plays a pivotal role in the pathophysiology of ACS. The current standard of treatmen...

journal_title：Clinical pharmacokinetics

authors： Teng R

更新日期：2012-05-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:Caspofungin is an echinocandin antifungal agent used as first-line therapy for the treatment of invasive candidiasis. The maintenance dose is adapted to body weight (BW) or liver function (Child-Pugh score B or C). We aimed to study the pharmacokinetics of caspofungin and assess pharmacokineti...

journal_title：Clinical pharmacokinetics

authors： Martial LC,Brüggemann RJ,Schouten JA,van Leeuwen HJ,van Zanten AR,de Lange DW,Muilwijk EW,Verweij PE,Burger DM,Aarnoutse RE,Pickkers P,Dorlo TP

更新日期：2016-06-01 00:00:00

abstract：:Morphine, morphine-6-glucuronide (M6G), morphine-3-glucuronide (M3G) and normorphine were analysed with high performance liquid chromatography in plasma and urine, collected over 72 h after administration of single intravenous 5 mg and oral 20 mg doses of morphine to 7 healthy volunteers. Systemic plasma clearance of ...

journal_title：Clinical pharmacokinetics

authors： Hasselström J,Säwe J

更新日期：1993-04-01 00:00:00

abstract：:Aminoglycosides are important antibacterial agents for the treatment of serious infection. Evidence suggests that high peak plasma concentrations must be achieved early in the course of treatment if these agents are to be effective, but prolonged high concentrations may cause ototoxicity and nephrotoxicity. Peak plasm...

journal_title：Clinical pharmacokinetics

authors： Barclay ML,Begg EJ,Hickling KG

更新日期：1994-07-01 00:00:00

abstract：OBJECTIVE:To assess any pharmacokinetic interactions between loperamide and saquinavir. DESIGN:Double-blind, double-dummy, randomised, placebo-controlled, three-way crossover trial. PARTICIPANTS:Twelve healthy male and female volunteers, aged 24-46 years. METHODS:Saquinavir and loperamide pharmacokinetics were deter...

journal_title：Clinical pharmacokinetics

authors： Mikus G,Schmidt L,Burhenne J,Ding R,Riedel KD,Tayrouz Y,Weiss J,Haefeli WE

更新日期：2004-01-01 00:00:00

abstract：BACKGROUND:Pemetrexed is used for the treatment for non-small cell lung cancer and mesothelioma. Patients with renal impairment are withheld treatment with this drug as it is unknown what dose is well tolerated in this population. OBJECTIVE:The purpose of our study was to investigate the pharmacokinetics (PK) of pemet...

journal_title：Clinical pharmacokinetics

authors： de Rouw N,Boosman RJ,Huitema ADR,Hilbrands LB,Svensson EM,Derijks HJ,van den Heuvel MM,Burger DM,Ter Heine R

更新日期：2021-01-09 00:00:00

abstract：:Escitalopram is the (S)-enantiomer of the racemic selective serotonin reuptake inhibitor antidepressant citalopram. Clinical studies have shown that escitalopram is effective and well tolerated in the treatment of depression and anxiety disorders. Following oral administration, escitalopram is rapidly absorbed and rea...

journal_title：Clinical pharmacokinetics

authors： Rao N

更新日期：2007-01-01 00:00:00

abstract：:Warfarin, like all the 4-hydroxycoumarin compounds, has an asymmetric carbon atom. The clinically available warfarin preparations consist of a racemic mixture of equal amounts of 2 distinct S and R isomers, the former being 4-times more potent as anticoagulant and more susceptible to drug interaction. Warfarin is high...

journal_title：Clinical pharmacokinetics

authors： Palareti G,Legnani C

更新日期：1996-04-01 00:00:00

abstract：:There are considerable laboratory data and information from animal and continuous culture in vitro models to support continuous infusion therapy for penicillins and cephalosporins, but, as yet, the only existing clinical data relate to cephalosporins. Penicillins do not exert concentration-dependent killing in the the...

journal_title：Clinical pharmacokinetics

authors： MacGowan AP,Bowker KE

更新日期：1998-11-01 00:00:00

abstract：:Vedolizumab is a humanized anti-α4β7 integrin monoclonal antibody that selectively blocks trafficking of memory T cells to inflamed gut tissue by inhibiting the α4β7-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) interaction. Approved for treating patients with moderately to severely active ulcerative colitis (...

journal_title：Clinical pharmacokinetics

authors： Rosario M,Dirks NL,Milch C,Parikh A,Bargfrede M,Wyant T,Fedyk E,Fox I

更新日期：2017-11-01 00:00:00

abstract：OBJECTIVE:To investigate the effect of concomitant administration of dairy products on the pharmacokinetics and tolerability of moxifloxacin. DESIGN:This was a single-centre, randomised, controlled, nonblinded, 2-way crossover study in healthy volunteers. PARTICIPANTS:12 healthy men (aged 25 to 46 years) were enrolle...

journal_title：Clinical pharmacokinetics

authors： Stass H,Kubitza D

更新日期：2001-01-01 00:00:00

abstract：:Calcineurin inhibitors, the primary immunosuppressive therapy used to prevent alloreactivity of transplanted organs, have a narrow therapeutic index. Currently, treatment is individualized based on clinical assessment of the risk of rejection or toxicity guided by trough concentration monitoring. Advances in immune mo...

journal_title：Clinical pharmacokinetics

authors： Leino AD,Pai MP

更新日期：2020-11-01 00:00:00

abstract：BACKGROUND:Fondaparinux sodium is a novel antithrombotic agent, the first of a new class of selective factor Xa inhibitors. It has favourable pharmacokinetics including 100% bioavailability, low variability and a mean terminal half-life of 17 hours for young and 21 hours for elderly healthy volunteers, enabling once-da...

journal_title：Clinical pharmacokinetics

authors： Paolucci F,Claviés MC,Donat F,Necciari J

更新日期：2002-01-01 00:00:00

abstract：:The use of liposomal carriers and the modification of therapeutic molecules through the attachment of poly(ethylene glycol) [PEG] moieties ('pegylation') are the most common approaches for enhancing the delivery of parenteral agents. Although 'classical' liposomes (i.e. phospholipid bilayer vehicles) have been effecti...

journal_title：Clinical pharmacokinetics

authors： Harris JM,Martin NE,Modi M

更新日期：2001-01-01 00:00:00

abstract：:Antipyrine pharmacokinetics were studied in 6 healthy women before and 2, 8 and 12 weeks after administering the injectable progestagen (progestin), norethisterone (norethindrone) enanthate 200mg intramuscularly. Additionally, antipyrine kinetics in 5 women who had previously used the injectable contraceptive for 8 to...

journal_title：Clinical pharmacokinetics

authors： Joshi JV,Gupta KC,Hazari KT,Gokral J,Pohujani S,Satoskar R

更新日期：1986-03-01 00:00:00

abstract：:Esmolol is an ultra short-acting intravenous cardioselective beta-antagonist. It has an extremely short elimination half-life (mean: 9 minutes; range: 4 to 16 minutes) and a total body clearance [285 ml/min/kg (17.1 L/h/kg)] approaching 3 times cardiac output and 14 times hepatic blood flow. The alpha-distribution hal...

journal_title：Clinical pharmacokinetics

authors： Wiest D

更新日期：1995-03-01 00:00:00

abstract：:The pharmacokinetic effect of extracorporeal elimination can be evaluated from the extracorporeal elimination rate constant, from the amount of drug removed, and from extracorporeal clearance. To compare the validity of these approaches in clinical practice, the effect of multiple plasma exchanges on the steady-state ...

journal_title：Clinical pharmacokinetics

authors： Keller F,Kreutz G,Vöhringer HF,Offermann G,Distler A

更新日期：1985-11-01 00:00:00

abstract：:Drugs from a wide range of pharmacological classes are commonly given to women in childbirth, either for a maternal effect or a fetal/neonatal effect. A number of striking physiological and biochemical changes occur during labour and delivery that might alter drug kinetics. The rate of drug absorption from the gastroi...

journal_title：Clinical pharmacokinetics

authors： Nation RL

更新日期：1980-07-01 00:00:00

abstract：INTRODUCTION:Renal impairment may have a significant impact on the pharmacokinetics of drugs. Ad hoc studies in subjects with renal impairment are required by the regulatory authorities to propose dose adjustments in these subjects, to find a dosing regimen able to provide a systemic exposure similar to those in subjec...

journal_title：Clinical pharmacokinetics

authors： Borella E,Poggesi I,Magni P

更新日期：2018-04-01 00:00:00

abstract：OBJECTIVE:A prospective pharmacokinetic study was performed in Caucasian patients from an intensive care unit with respiratory support to evaluate the influence of this circumstance on the pharmacokinetic behaviour of levofloxacin. PATIENTS AND METHODS:A standard dosage regimen of 500 mg/day was administered to nine C...

journal_title：Clinical pharmacokinetics

authors： Sánchez Navarro A,Colino Gandarillas CI,Alvarez Lerma F,Menacho YA,Domínguez-Gil A

更新日期：2005-01-01 00:00:00

abstract：:According to recent clinical consensus, pharmacotherapy of inflammatory bowel disease (IBD) is, or should be, personalized medicine. IBD treatment is complex, with highly different treatment classes and relatively few data on treatment strategy. Although thorough evidence-based international IBD guidelines currently e...

journal_title：Clinical pharmacokinetics

authors： Derijks LJJ,Wong DR,Hommes DW,van Bodegraven AA

更新日期：2018-09-01 00:00:00

abstract：:The effects of diabetes mellitus on the pharmacokinetics and pharmacodynamics of drugs have been well described in experimental animal models; however, only minimal data exist for humans and the current knowledge regarding the effects of diabetes on these properties remains unclear. Nevertheless, it has been observed ...

journal_title：Clinical pharmacokinetics

authors： Dostalek M,Akhlaghi F,Puzanovova M

更新日期：2012-08-01 00:00:00

abstract：:Clarithromycin is a semisynthetic macrolide antibiotic, structurally related to erythromycin. It has a more favourable pharmacokinetic profile than erythromycin, thus allowing twice-daily administration and possibly increasing compliance among outpatients. Clarithromycin is well absorbed from the gastrointestinal trac...

journal_title：Clinical pharmacokinetics

authors： Fraschini F,Scaglione F,Demartini G

更新日期：1993-09-01 00:00:00

abstract：:A large body of evidence suggests that not only direct anticoagulant effects but also major bleeding events and stroke prevention depend on plasma concentrations of direct oral anticoagulants (DOACs). Concomitant drugs that cause drug-drug interactions (DDIs) alter DOAC exposure by increasing or decreasing DOAC bioava...

journal_title：Clinical pharmacokinetics

authors： Foerster KI,Hermann S,Mikus G,Haefeli WE

更新日期：2020-08-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:This analysis used a population pharmacokinetic approach to identify covariates that influence plasma exposure of liraglutide 3.0 mg, a glucagon-like peptide-1 (GLP-1) receptor agonist approved for weight management in overweight and obese individuals. METHODS:Samples for pharmacokinetic anal...

journal_title：Clinical pharmacokinetics

authors： Overgaard RV,Petri KC,Jacobsen LV,Jensen CB

更新日期：2016-11-01 00:00:00

abstract：:Ethnic or racial differences in pharmacokinetics and pharmacodynamics have been attributed to the distinctions in the genetic, physiological and pathological factors between ethnic/racial groups. These pharmacokinetic/pharmacodynamic differences are also known to be influenced by several extrinsic factors such as soci...

journal_title：Clinical pharmacokinetics

authors： Chen ML

更新日期：2006-01-01 00:00:00

abstract：:Haloperidol has been used extensively for the treatment of psychotic disorders, and it has been suggested that the monitoring of plasma haloperidol concentration is clinically useful. Different assay methodologies have been used in research and clinical practice to examine the relationship between response and plasma ...

journal_title：Clinical pharmacokinetics

authors： Froemming JS,Lam YW,Jann MW,Davis CM

更新日期：1989-12-01 00:00:00

abstract：:The effects of anaesthesia and surgery on the pharmacokinetics of ketobemidone were studied in 12 patients. Plasma ketobemidone concentrations were assayed with a mass-fragmentographic method. The peroperative Vd(area) was 5.9 +/- 2.6L/kg and the terminal half-life was 3.9 +/- 1.7 h. In the postoperative period Vd(are...

journal_title：Clinical pharmacokinetics

authors： Tamsen A,Bondesson U,Dahlström B,Hartvig P

更新日期：1982-05-01 00:00:00

abstract：:The overall reporting rate of drug-drug interactions with fluvoxamine is very low: only 73 cases have been identified from an estimated exposure of over 8 million patients worldwide. The reporting rate is similar in men and women, and most events relate to the use of fluvoxamine in conjunction with psychotropic compou...

journal_title：Clinical pharmacokinetics

authors： Wagner W,Vause EW

更新日期：1995-01-01 00:00:00